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Abstract The province of KwaZulu-Natal has the highest
prevalence of HIV in South Africa, particularly among
young women. In order to more closely examine the HIV
prevalence and incidence in non-pregnant women from
rural, semi-rural and urban areas, data from 5,753 women
screened for enrolment into three HIV prevention studies
were combined and analysed. The prevalence of HIV
infection was 43% at screening. HIV incidence among the
2,523 enrolled HIV-negative women was determined every
quarter, and sexual behaviour and socio-demographic data
were collected as per respective protocols. During follow-
up, 211 women seroconverted (6.6/100 women years).
Multivariate analysis found that seroconversion rates were
highest among women who were B24 years old, single and
not cohabiting, and who had incident sexually transmitted
infections. The epidemic in KwaZulu-Natal calls for tar-
geted HIV prevention interventions among those at highest
risk of acquiring or transmitting infection.
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Introduction
Sub-Saharan Africa is home to more than 60% of the total
number of people living with HIV/AIDS [1]. Many coun-
tries in this region are said to have a ‘‘generalized epi-
demic’’ defined as having HIV prevalence rates of more
than 1% in the adult population aged between 15–59 years
and of more than 5% among populations at high risk (such
as those with sexually transmitted infections (STIs)) [2].
The dominant mode of HIV transmission in the region is
unprotected heterosexual sex. Factors which exacerbate
the risk of HIV transmission are transactional sex [3, 4],
multiple concurrent partnerships [5, 6], co-infection with
viral and bacterial STIs [7, 8], lack of male circumcision
[9, 10], and migration [11–13]. Age and gender are also
important predictors of vulnerability to HIV infection, with
younger women more vulnerable to HIV infection than
men of the same age [14].
Unfortunately, the HIV epidemic continues to affect
South Africa, and particularly South African women, dis-
proportionately. The province of KwaZulu-Natal (KZN) is
home to 9.4 million people. HIV prevalence in KZN
increased by 8.6% between 2002 and 2008 to 23.5% [14],
and the province has an antenatal HIV prevalence of nearly
40% [15]. HIV prevalence rates have always been higher in
KZN than in any other province in South Africa, and this
trend has been sustained since the early 1990s. This region
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is therefore considered to be the epicentre of the HIV/AIDS
epidemic in South Africa, the area most in need of an
effective HIV prevention method for women [16].
Previously, the evidence has suggested that HIV prev-
alence was generally higher in large urban areas compared
with rural areas—residents of urban informal areas were
found to have an HIV prevalence of 25.8%, compared with
a prevalence of 13.9% for residents of both rural and urban
formal areas, and 17.3% for those residing in rural informal
areas [17]. However, residents of rural areas may have less
access to HIV testing, care and treatment than their urban
counterparts. Additional challenges for rural communities
may include poverty, lack of education, lack of access to
condoms and unemployment. These factors together with
cultural norms and values could influence the ability to
achieve correct and consistent use of male and female
condoms, the only widely available prevention technolo-
gies; this may lead to variations in HIV prevalence linked
to the socio-economic profile and geographical location of
communities.
Despite intensive condom counselling, many women in
southern Africa are unable to negotiate safe sex [16].
Accordingly, there has been growing interest in female-
initiated methods of HIV prevention. In recent years,
research has focused on topical microbicides, products
which can be discreetly applied inside the vagina before
sexual intercourse. In addition, barrier methods such as the
vaginal diaphragm have been tested for HIV prevention
[18]. Recently, proof of concept was provided by the
favourable results of the CAPRISA 004 trial of an anti-
retroviral-based microbicide [19], after many years of
discouraging trial outcomes—six other potential microbi-
cides and the vaginal diaphragm failed to prevent HIV
infection [18, 20–25].
We conducted two site preparedness studies for future
large scale HIV prevention trials, and an HIV prevention
phase III clinical trial of the vaginal diaphragm in cohorts
of women drawn from rural, semi-rural and urban com-
munities in KZN. Given that women participating in such
studies are requested to avoid pregnancy due to the
unknown teratogenic effects of the study products, these
investigations provided important information on the
status of the epidemic among non-pregnant women, a
demographic obviously excluded from antenatal surveys.
Data from these three studies have been combined to
describe the risk factors associated with HIV acquisition
overall, and to determine whether prevalence and inci-
dence differed by residential area. Direct HIV incidence
measures are of interest given that these are rare, difficult
to obtain, and are becoming increasingly important for
the opportunity they provide to assess the impact of
changes in HIV prevention programmes on seroconversion
patterns. Although BED capture enzyme immunoassay
(BED-CEIA) [26] and avidity index (AI) [27] assays have
been developed to estimate the incidence of HIV from
samples collected in cross-sectional surveys, the accuracy
of these remains to be optimised—BED-CEIA and AI tend
to over-estimate incidence rates [28–30], while serial HIV
prevalence surveys from which incidence may be calcu-
lated are expensive and suffer from limitations in repre-
sentativeness and difficulties associated with calculation
[31]. This combined dataset therefore provides a unique
opportunity for more specific measurement of HIV inci-
dence and associated risk factors in one of the most
severely affected areas in the world.
Methods
Study Sites
We combined data from 5,753 sexually active women
who consented to screening for three studies in KwaZulu-
Natal, South Africa. These studies were as follows:
Methods for Improving Reproductive Health in Africa
(MIRA) trial of the diaphragm for HIV prevention
(n = 3,492; September 2002–September 2005, undertaken
in rural Umkomaas and Botha’s Hill, southern and
western Durban, respectively) [18]; The Microbicides
Development Programme (MDP) Feasibility Study in
Preparation for Phase III Microbicide Trials (n = 1,226;
August 2002–September 2004, semi-rural Tongaat and
Verulam, northern Durban) [32], and the HIV Prevention
Trials Network (HPTN) Site Preparedness study for
Future Implementation of Phase II/IIb/III clinical trials
(n = 1,035; May 2003–January 2005, rural district of
Hlabisa, and urban centre in Durban) [16]. Results from
the MIRA trial indicated that use of the diaphragm did not
provide added protection against HIV over that provided
by condoms and an HIV prevention package [18]; we
were thus able to combine the data from this trial with
data from the cohort studies. The decision on the alloca-
tion of a given study site to the categories of ‘‘urban’’,
‘‘rural’’ or ‘‘semi-rural’’ was based upon the relative
population density and level of infrastructural develop-
ment of the communities surrounding each site. Thus
Umkomaas, Botha’s Hill and Hlabisa were considered to
be ‘‘rural’’ communities given the lower population den-
sity, minimal infrastructure and prevalence of subsistence
agricultural activities, while Verulam and Tongaat were
considered to be intermediate between these communities
and an urban area, since both of these towns provide
commercial and retail services to a wider population
residing in surrounding areas which are relatively less
developed, resulting in an overall intermediate population
mix for the clinics in Verulam and Tongaat.
AIDS Behav (2012) 16:2062–2071 2063
123
Population
All study populations have previously been described
elsewhere [16, 18, 32]. Women were recruited from
family planning, well-baby and general health clinics for
the MIRA study; in the HPTN 055 study, women were
recruited through community meetings and door-to-door
visits; while the MDP Feasibility study recruited women
from health centres, family planning clinics, and by
word-of-mouth. We also routinely conduct recruitment
activities at government agencies such as social welfare
grant offices.
Briefly, main eligibility criteria were similar for all
studies, and included: being sexually active; HIV-negative
status at screening; willingness to provide written consent
and follow study procedure; not pregnant with no intention
to become so; and anticipated residence in and around the
study area for a minimum of 1 year. Participants received
risk reduction counselling and access to condoms at all
visits. Counsellors emphasized that condoms are the only
known method to prevent acquisition of HIV and STIs, and
that condoms should be used for every sex act. While the
MIRA trial included an investigational arm which women
who enrolled may have been randomised to, and which
may have influenced their willingness to participate, both
HPTN 055 and the MDP Feasibility study were cohort
studies conducted in preparation for later trials, and women
were only requested to use condoms in these latter two
investigations.
Study Procedures
For the MIRA and HPTN 055 trials, HIV diagnostic testing
was achieved using two rapid tests on whole blood sourced
from either finger-prick or venepuncture (Determine HIV-
1/2 Abbott Laboratories, Tokyo, Japan and Oraquick
Orasure Technologies, Bethlehem, PA, USA). The Abbott
IMX ELISA test (Abbott Diagnostics, Johannesburg, South
Africa) in combination with the Vironostika HIV Uni-form
II plus O ELISA (previously Organon Teknika, USA,
currently bioMe´rieux, France) for positive and equivocal
results was used on whole blood sourced from venepunc-
ture for HIV diagnosis during the MDP Feasibility Study.
Only women who had an HIV test result were included in
the studies.
STI testing was undertaken by similar methods in all
studies [16, 18]; the methods used in the MDP Feasibility
Study have not previously been outlined and are presented
here: Chlamydia and gonorrhoea were assessed using PCR
(COBAS Amplicor, Roche Molecular Diagnostics, Pleas-
anton, CA, USA); syphilis by RPR and confirmatory TPHA
(Omega Diagnostics, Alva, UK); HSV2 by HerpeSelect
TM2 ELISA IgG (Focus Technologies, Cypress, CA,
USA); and bacterial vaginosis, Candida and T. vaginalis by
Gram stain, KOH and Whiff test, and wet mount micros-
copy, respectively. Participants were treated for curable
STIs prior to enrolment and assessed and treated for inci-
dent infections at each study visit.
Behavioural questionnaires to collect information such
as frequency of condom use and frequency of sex acts were
administered both by trained interviewers and via audio
computer assisted self interview.
Women who were HIV-positive at screening were
referred to local health care facilities for care and support.
Data on whether seropositive women were on antiretrovi-
rals at the time of screening were not collected. Women
who seroconverted during the trials remained in the study
and were provided with ongoing counselling and referral to
local health care facilities for further care upon completion
of the studies. All protocols and informed consent forms
were approved by the Biomedical Research Ethics Com-
mittee at the University of KwaZulu-Natal as well as the
various study-specific Institutional Review Boards.
Statistical Analysis
For each study/cohort, all relevant demographic, socio-
economic, sexual risk behaviors and biological factors
were pooled by participants’ unique identification numbers.
Data were combined by variables across trials to increase
the statistical power. SAS 9.2 data statements were used to
combine the available individual patient-level data before
the analysis was conducted. Categorical variables were
created using the same cut-points across the studies. Data
were not weighted since the primary concern was the
comparison of characteristics by residential area. Statistical
analysis was performed using STATA release 10.0 (Stata
Statistical Software, Stata Corporation, College Station,
Texas, TX, USA). Differences in proportions were tested
for statistical significance using the Chi square test. The
Student’s t test was used to compare continuous data.
Univariate and multivariate logistic regression analyses
were conducted to identify variables predictive of HIV
infection at screening.
For the analyses presented here, we only considered
those sociodemographic and behavioural characteristics
which were assessed consistently across all three studies
at screening. Variables included in this analysis were
region of residence (urban, semi-rural, rural); age; marital
status; relationship and cohabitation status; education level;
being diagnosed with any STIs at baseline or thereafter
(Chlamydia, gonorrhoea, syphilis or T. vaginalis) and
incident pregnancy.
The incidence rate for HIV infection, expressed as time
to seroconversion, was estimated for women who were
HIV-negative at screening and satisfied the eligibility
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criteria. The date of seroconversion was estimated using
the midpoint between the last negative and the first positive
antibody test results within the follow-up period. Associ-
ations between various independent factors and HIV
seroconversion were assessed with Kaplan–Meier survival
plots, log-rank tests and in a multivariate model using Cox
proportional hazard regression analysis. Risk factors of
interest were residential area (rural or semi-rural vs. urban);
age (expressed in the age groups B24, 25–34 and 35 or
more); relationship and cohabitation status; education level
(high school or less); condom use during last sexual act and
contraception use (male condoms, natural methods, pills,
female condoms, injectables and surgical sterilization).
Multivariate models were created that included all vari-
ables found to be statistically significant (P \ 0.1) in uni-
variate analyses and used forward stepwise methods.
Results
Overall socio-demographic characteristics of the study
population are presented, as well as by rural, semi-rural and
urban residence in Table 1. Of the 5,753 women who
consented to screening for HIV status, 3,994 (70%) were
from a rural region, 1,226 (21%) from a semi-rural region,
and 533 (9%) from an urban region. Overall the combined
study population had a median age of 27 years (inter-
quartile range (IQR): 22–34). Most of the women were
single and non-cohabiting (87%). Approximately 40% of
the women had less than a high school education. The total
number of person years that women were at risk was
3171.96. The retention rates in the studies were 94%
(MIRA), 97 and 94% (HPTN 055 at Durban and Hlabisa,
respectively), and 67% (MDP Feasibility study).
Prevalence of HIV Infection at Screening
A total of 2,369 participants (43%) were HIV-positive at
screening (Table 1). HIV infection at screening differed
significantly by area of residence (P = 0.0002). The pro-
portion of women who were aged 35 years or older was
highest in rural and semi-rural areas compared to urban
areas. Having less than high school education was highest
among rural residents compared to semi-rural and urban.
Rural and semi-rural residents were more likely than urban
residents to be single and non-cohabiting (marital status
was self-reported).
HIV prevalence for the age groups B24, 25–34, and
35? years was 38, 52 and 30%, respectively.
Table 2 presents the results of univariate and multivari-
ate logistic regression analyses of characteristics of women
who tested positive for HIV infection at screening. Living in
a semi-rural residential area, being between the ages of 25
and 34 years, single and non-cohabiting, and being diag-
nosed with any STIs at baseline (Chlamydia, gonorrhoea,
syphilis or T. vaginalis) were all significant independent
predictors of HIV infection in multivariate analysis.
Incidence of HIV Seroconversion During Follow-Up
A total of 2,523 HIV-negative women were eligible and
enrolled in the three studies, with a median duration of
Table 1 Demographic characteristics, HIV and STI prevalence at screening in three communities of women from different geographical areas
and overall
Variables Overall N (%) Urbana N (%) Ruralb N (%) Semi-ruralc N (%) Z value
Number of women (%) 5,753 (100) 533 (9) 3,994 (70) 1,226 (21)
HIV at screening 2,369 (43) 190 (40) 1,605 (41) 574 (47) 2.72**
STId at screening 788 (14) 132 (27) 620 (16) 70 (6) 5.63**
Age, median (IQR) 27 (22–34) 26 (22–30) 27 (22–34) 28 (23–36)
Age groups (years) 6.75**
B24 2,214 (38) 226 (42) 1,598 (40) 390 (32)
25–34 2,181 (38) 238 (45) 1,456 (36) 487 (40)
35? 1,358 (24) 69 (13) 939 (24) 350 (28)
Education:
Less than high school 2,382 (41) 137 (26) 1,912 (47) 334 (27) 7.14**
Single, non-cohabiting 5,033 (87) 434 (81) 3,461 (87) 1,138 (93) 3.98**
a Urban Durban only (not all screened participants tested for HIV (n = 481) or STI (n = 484))
b Rural districts of Hlabisa (number of patients tested for HIV = 435), Umkomaas and Botha’s Hill (southern and western Durban)
c Tongaat and Verulam (northern Durban)
d Chlamydia, gonorrhoea, syphilis or T. vaginalis
** P values \0.01
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follow-up of 12 months. Of these, a total of 211 women
seroconverted during the follow-up period (August 2002–
September 2005) (incidence rate 6.6/100 women-years).
The Kaplan–Meier survival curves of HIV infection strat-
ified by age and cohabitation status with the woman’s
regular sexual partners are shown in Fig. 1a and b respec-
tively. The crude incidence rate was highest in women
24 years of age or younger (10/100 women-years), and
second highest among single, non-cohabiting woman
(6.4/100 women-years). The incidence rates in women
aged 25–34 and 35? years were 6/100 women-years and
3.6/100 women-years, respectively.
Table 3 presents the results of univariate and multivari-
ate Cox proportional hazard analyses of demographic
characteristics and their association with time to HIV sero-
conversion. Univariate analyses showed that baseline STI
infection (Chlamydia, gonorrhoea, syphilis or T. vaginalis)
(hazard ratio (HR) 1.52, 95% confidence Interval (CI) 1.07,
2.15), incident STIs (HR 2.17, 95% CI 1.66, 2.84), incident
pregnancy (HR 2.07, 95% CI 1.58, 2.73), being aged 25–34
(HR 1.69, 95% CI 1.10, 2.60), being 24 years of age or
younger (HR 2.78, 95% CI 1.88, 4.11), being a single, non-
cohabiting woman (HR 4.76, 95% CI 2.60, 8.74), and
having used a condom at the last sex act (baseline) (HR
1.47, 95% CI 1.12, 1.96), were all significantly associated
with increased risk of HIV seroconversion. No significant
associations with time to seroconversion were observed for
geographical area, baseline education level, employment
status, baseline contraception use, and number of sex acts in
the week before seroconversion.
At the multivariate level, incident STIs (HR 1.90, 95%
CI 1.45, 2.50), being B24 years old (HR 1.85, 95% CI
1.24, 2.77), and being a single, non-cohabiting woman (HR
3.43, 95% CI 1.83, 6.42), were all significantly associated
with increased risk of HIV seroconversion.
Discussion
The combined data from these three studies clearly suggest
a very generalized and severe epidemic of HIV among a
select population of non-pregnant women in the greater
Durban region of KwaZulu-Natal, South Africa.
The overall incidence of HIV infection was unaccept-
ably high at 6.6/100 woman years—almost double the
incidence for non-pregnant women calculated from a
country-wide prevalence survey conducted during a similar
time period (3.8%) [33]. The incidence rate was highest
among women 24 years of age or younger, in contrast to
the peak of prevalent HIV infection, which was found
among women aged 25–35 years, a pattern also noted by
Rehle et al. [34] for data gathered between 2002 and 2005.
We believe this difference may be a reflection of the slow
uptake of HIV testing in these populations—older women
may have had undetected chronic infections of several
years duration, with the date of seroconversion occurring
when they were probably under the age of 24 years. Other
authors have found that many women older than 25 years
of age were undergoing HIV testing for the first time
during screening for clinical trials [35]. Rehle et al. [34]
consider that the roll-out of antiretroviral therapy has
resulted in an ‘‘excess’’ of prevalent HIV infections with a
peak of excess infections in women aged 25 years and
older, which overlaps with our findings. However, this is
unlikely to be the primary explanation for the high HIV
prevalence in the 25–35 year age group, since roll-out of
Table 2 Risk factors for being diagnosed with HIV infection at screening
Variable Univariate analysis Multivariate analysis
Odds ratio (95% CI) z value Odds ratio (95% CI) z value
District
Urban 1 1 –
Rural 1.14 (0.95, 1.38) 1.41 1.15 (0.94, 1.40) 1.33
Semi-rural 1.46 (1.19, 1.80) 2.60** 1.36 (1.10, 1.70) 2.31**
STIa at screening 1.56 (1.34–1.83) 2.85** 1.27 (1.08–1.48) 2.25**
Age groups (years)
35? 1 – –
25–34 2.62 (2.27, 3.03) 3.62** 2.09 (1.79, 2.44) 2.52**
B24 1.41 (1.22, 1.63) 1.23** 0.97 (0.83, 1.13) -0.31
Less than high school education 0.99 (0.90, 1.10) -0.21 – –
Single, non-cohabiting 6.11 (4.86, 7.70) 5.39** 6.07 (4.78, 7.70) 5.31**
a Chlamydia, gonorrhoea, syphilis and T. vaginalis
* P value \0.05
** P value \0.01
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ARVs for treatment only began in 2004 [36] in South
Africa and the studies included in this analysis collectively
spanned a time period from 2002 to 2005.
A tentative comparison with the incidence rates for the
period 2002–2005 calculated by Rehle and colleagues [34]
may be made: those authors calculated a nation-wide
incidence rate of 5.5/100 person years for women aged
15–24 years from national HIV survey data, which is only
approximately half that found for women aged 24 years or
younger in our combined cohort (10/100 woman-years).
Directly measured incidence data are available from a
study conducted by the Africa Centre in Hlabisa spanning
2003–2005 [37], which showed that the highest incidence
of HIV occurred among women 25–29 years of age (crude
incidence rate 8/100 wy), while women 20–24 years of age
had a crude incidence rate of 5.6/100 woman years; total
incidence for women between the ages of 15 and 49 years
was 3.8/100 woman years. Similarly, Abdool Karim et al.
[35] found the highest overall HIV incidence rate among
women 25 years of age or older (8.7/100 wy) in two
communities in KwaZulu-Natal (one rural and one urban),
while our data show peak HIV incidence among women
24 years of age or younger. While differences in the study
methods and age categorisation complicate the comparison,
it is clear that the HIV incidence in women in their twenties
is extremely high in these studies. The recently completed
CAPRISA 004 trial [19] also enables comparison of HIV
incidence rates in the placebo arm with our data for similar
geographic locations; the overall HIV incidence rate in the
placebo arm was 9.1/100 woman years for the years
2007–2010, slightly higher than our overall figure (6.6/100
wy) for an earlier measurement period. Those authors also
did not find a significant difference in incidence rates
between rural and urban sites (for either active or placebo
arms), in agreement with our results which indicate no
significant difference in risk of seroconversion by resi-
dential area (urban or rural). Taken together, these data
indicate the seriousness of the epidemic in KwaZulu-Natal
and the potential future burden on health-care resources in
that province as a result of HIV-related morbidity.
Risk of HIV seroconversion was also higher among
women who used condoms (at last sexual act—baseline
measurement) in comparison to women who did not. This
apparently counterintuitive finding could be explained by
patterns of sexual risk-taking in those who use condoms;
condom usage has been found to be more common among
men who have several casual partners [13], and usage with
regular partners is unusual [38], indicating that measures of
condom use may possibly be considered proxies for the
level of risky sexual behaviour in sub-Saharan Africa i.e.
persons who perceive themselves to be at high risk are
more likely to both use condoms and be at risk of acquiring
HIV.
The incidence of HIV seroconversion was higher among
women who were single and non-cohabiting. We chose to
explore this demographic in particular to illustrate the
comparative risk of HIV acquisition in association with
relationship status. We would hypothesise that the young,
single, non-cohabiting women in our studies may have
been involved in sexual contacts which were characterised
by power asymmetries (e.g. transactional and/or intergen-
erational sex [3, 39, 40]); this could be the reason why
these women were more vulnerable to HIV acquisition. In
addition, these women may have been involved in multiple
concurrent relationships [6], or long-term established non-
cohabiting relationships in which condom use may have
decreased due to increased trust of the partner [41], both of
which could increase their vulnerability to HIV.
Our data did not confirm a higher risk of prevalent HIV
in urban populations, even though this group had the
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at risk of being HIV positive at screening. This is in con-
trast to the findings of Abdool Karim et al. [35] who found
a significant difference in HIV prevalence between cohorts
of women living in rural and urban areas; those authors did
not, however, note a significant overall difference in HIV
incidence between the two locales. In addition to the
25–34 year age group, those living in a semi-rural area,
those who were single and non-cohabiting, and those
diagnosed with an STI such as Chlamydia, gonorrhoea,
syphilis or T. vaginalis were most likely to be HIV infected
at baseline.
Level of education did not appear to have any effect on
risk of HIV infection either at screening or during follow-up.
Earlier research in Africa suggested that higher levels of
education and employment were correlated with greater risk
of HIV infection, and that the association was more
pronounced in rural areas [42]. However, this pattern
has changed over time. Lurie et al. [43] showed that
Table 3 Risk factors for HIV seroconversion during follow-up (analysis by Cox proportional hazard regression)
Variable Univariate analysis Multivariate analysis
N (%) HR (95% CI) z value HR (95% CI) z value
Any STIa at screening 316 (13) 1.52 (1.07, 2.15) 2.80* – –
Any STIa during the follow-up
(time dependent)
711 (28) 2.17 (1.66, 2.84) 4.80** 1.90 (1.45, 2.50) 3.90**
Pregnancy during the follow-up
(time-dependent)
566 (22) 2.07 (1.58, 2.73) 3.85** –
Age (years)
35? 784 (31) 1 1
25–34 774 (31) 1.69 (1.10, 2.60) 2.80* 1.39 (0.90, 2.15) 1.45
B24 965 (38) 2.78 (1.88, 4.11) 3.80** 1.85 (1.24, 2.77) 3.03**
District
Urban 238 (10) 1
Rural 1,720 (68) 1.15 (0.63, 2.10) 0.75 – –
Semi-rural 565 (22) 1.39 (0.73, 2.66) 1.37 – –
Less than high school education
Yes 1,674 (66) 0.86 (0.64, 1.14) 0.300 (-1.43) –
No 849 (34) 1 – –
Employed/income
No 2,000 (79) 1.47 (1.01, 2.14) 2.04*
Yes 523 (21) 1 – –
Single and non-cohabiting?
Nob 1,958 (78) 1 1 –
Yes 565 (22) 4.76 (2.60, 8.74) 4.41** 3.43 (1.83, 6.42) 3.70**
Condom used during last sexual act (baseline)
No 1,219 (48) 1 – –
Yes 1,304 (52) 1.47 (1.12, 1.96) 2.31** – –
Contraception use at baselinec
No 1,012 (40) 1 – –
Yes 1,511 (60) 0.95 (0.71, 1.26) -0.26 – –
Typical number of sex acts in week
before seroconversion
Less than 3 acts 991 (39) 1
3 plus acts 1,532 (61) 1.35 (1.01, 1.82) 2.08* –
a Chlamydia, gonorrhoea, syphilis or T. vaginalis
b All other marriage and cohabitation combinations e.g. married and cohabiting, married and non-cohabiting, single and cohabiting
c Male condoms, natural methods, pills, female condoms, injectables and surgical sterilisation
* P value \0.05
** P value \0.01
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HIV-infected adults in South Africa with a higher education
level were more likely to use condoms with regular partners.
The same study also suggested that school enrolment was
strongly associated with protective sexual behaviour, with
correspondingly lower HIV infection. The lack of a signifi-
cant association of HIV prevalence and incidence with
educational level in our studies may suggest that the disease
has become so widespread in the study population that this
distinction has fallen away.
Women’s sexual negotiating power is compromised in
transactional sexual relationships [44], and promoted by
economic independence [45]. However we found that
employment or receipt of regular income did not signifi-
cantly reduce the risk of HIV acquisition.
The relationship between incident STIs and increased risk
of HIV seroconversion [46] was confirmed in this study (for
Chlamydia, gonorrhoea, syphilis or T. vaginalis). These
findings underscore the association of younger age with both
HIV and STIs, and reinforce the need for improved sexual
health and behavioural counselling services to facilitate
early detection and treatment of STIs, and to promote safer
sexual practices to prevent later acquisition of HIV.
Our analyses are unique in that we were able to combine
several databases from multiple studies to provide a more
in-depth understanding of the HIV epidemic in KwaZulu-
Natal, the epicentre of the HIV epidemic in South Africa.
Our results underscore an urgent need for interventions that
specifically target young, single, non-cohabiting women;
these include the development of new female-initiated HIV
prevention options, women empowerment initiatives, and
aggressive promotion of female condoms. In addition,
emphasis should be placed on education of both sexual
partners on other prevention options (such as male cir-
cumcision). It is also important to promote faithfulness and
monogamy to avoid the risk of HIV acquisition.
Our analyses have several limitations. We could not
determine the characteristics of women who did not present
for screening, and therefore must exercise caution in
extrapolating our results to the population as a whole.
However, the results, at the least, provide valuable infor-
mation about the characteristics of women who volunteer
for HIV prevention studies in KwaZulu-Natal. We were
only able to analyse factors influencing HIV acquisition
which were measured in the various studies, and this may
have limited our ability to identify such factors; the inde-
pendent variables included are limited. We were unable to
determine if the difference in average age of the popula-
tions of screened women was due to the overall demo-
graphics of the surrounding population, or whether the
differences arose from variations by area and age in will-
ingness to be screened. Due to the variation of questions in
collecting behavioural and socio-demographic data, we
were unable to merge many key components of
behavioural risk characteristics such as partner turnover;
similarly, a common protocol was not used across all three
studies, and we therefore cannot be sure that all categori-
zations are the same. This may have reduced the power of
the analyses to detect significant associations. Given the
geographical location of the study sites, we were able to
target more rural women than urban women. However, no
data concerning migration were included in these analyses.
Lastly we were unable to collect any sexual behaviour data
from male partners of the women.
In conclusion, this study provides a valuable direct
measure of the high incidence of HIV among non-pregnant
women participating in HIV prevention studies in multiple
communities in KwaZulu-Natal. We provide clear evi-
dence that young, single, non-cohabiting women are most
likely to acquire HIV and urge the authorities to provide a
rapid response by scaling up HIV prevention, treatment and
care efforts in all these communities.
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